Earnings call
Indoco Remedies Q3 FY26 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company is confident that its Europe base business will grow at double-digit, and expects Europe revenues to grow at 20% plus over the next few years, with new products offering better market opportunity and margins and being made in optimized plants. The company expected maintenance capex of around 35, 40 max per annum. Standalone net revenues were INR3,896 million in the third quarter financial year 2025-'26, compared with INR3,649 million in the same quarter last year and INR4,293 million in Q2 financial year '25-'26, representing 6.8% growth year over year and negative 9% growth quarter over quarter. Cyclopam grew by 30% at primary last year while prescriptions grew by 16%; this year primary was 15% down, but prescriptions continued to grow. About 40% of the API sales Indoco Remedies Limited sells outside is supplied internally to in-house formulations at Indoco.
The numbers management gave
Results
- Standalone net revenues were INR3,896 million in the third quarter financial year 2025-'26, compared with INR3,649 million in the same quarter last year and INR4,293 million in Q2 financial year '25-'26, representing 6.8% growth year over year and negative 9% growth quarter over quarter.
Show source
Standalone net revenues of the company for the third quarter financial year 2025-'26 are at INR3,896 million compared to INR3,649 million for the same quarter last year and INR4,293 million for the immediately preceding quarter, that is Q2 financial year '25-'26, at 6.8% and negative 9% growth, respectively.
- Consolidated net revenues were INR4,343 million in the third quarter financial year 2025-'26, compared with INR4,025 million in the same quarter last year and INR4,718 million in Q2 financial year '26, representing 7.9% positive growth year over year and 7.9% negative growth quarter over quarter.
Show source
Consolidated net revenues of the company for the third quarter financial year 2025-'26 are at INR4,343 million compared to INR4,025 million for the same quarter last year and INR4,718 million for the immediately preceding quarter, that is Q2 financial year '26 at 7.9% positive and 7.9% negative, respectively.
- Standalone EBITDA to net sales was 6.6% at INR259 million in the third quarter financial year 2025-'26, compared with 5.5% at INR201 million in the same quarter last year and 12.4% at INR534 million in Q2 financial year '25-'26.
Show source
Standalone EBITDA to net sales for the quarter is at 6.6% at INR259 million compared to 5.5% at INR201 million same quarter last year.
- Consolidated EBITDA to sales was 7.3% at INR315 million in the third quarter financial year 2025-'26, compared with 3% at INR120 million in the same quarter last year.
Show source
Consolidated EBITDA to sales for the quarter is 7.3% at INR315 million compared to 3% at INR120 million same quarter last year.
- Domestic Formulation business revenue was INR2,142 million in Q3 FY '26, compared with INR2,241 million in the same quarter last year.
Show source
Revenues from Domestic Formulation business for the quarter are INR2,142 million as compared to INR2,241 million same quarter last year.
- Vitamins, anti-diabetes, anti-infectives and respiratory therapeutic segments performed well in Q3 FY '26 compared with the same quarter last year.
Show source
Major therapeutic segments like vitamins, anti-diabetes, anti-infectives and respiratory performed well during the quarter as compared to the same quarter last year.
Show 19 more statements
Results
- International Formulation business revenue grew by 26.2% to INR1,356 million in Q3 FY '26, compared with INR1,074 million in the same quarter last year.
Show source
On the International business front, revenues from International Formulation business grew by 26.2% at INR1,356 million compared to INR1,074 million same quarter last year.
- Regulatory markets revenue grew by 25.9% to INR861 million in Q3 FY '26, compared with INR684 million in the same quarter last year.
Show source
Revenues from regulatory markets for the quarter grew by 25.9% at INR861 million as against INR684 million same quarter last year.
- U.S. business revenue grew by 21.6% to INR341 million in Q3 FY '26, compared with INR280 million in the same quarter last year.
Show source
Revenues from U.S. business for the quarter grew by 21.6% at INR341 million as compared to INR280 million same quarter last year.
- Europe revenue grew by 36.9% to INR485 million in Q3 FY '26, compared with INR354 million in the same quarter last year.
Show source
Revenues from Europe for the quarter grew by 36.9% at INR485 million as against INR354 million same quarter last year.
- Revenue from the [Inaudible 00:07:48] market was INR35 million in Q3 FY '26, compared with INR49 million in the same quarter last year.
Show source
Revenues from [Inaudible 00:07:48] market for the quarter are INR35 million as against INR49 million same quarter last year.
- Emerging markets revenue grew by 26.8% to INR495 million in Q3 FY '26, compared with INR390 million in the same quarter last year.
Show source
Page 3 of 17 Indoco Remedies Limited February 03, 2026 Revenues from emerging markets for the quarter grew by 26.8% at INR495 million as against INR390 million same quarter last year.
- API business revenue grew by 24% to INR344 million in Q3 FY '26, compared with INR278 million in the same quarter last year.
Show source
Revenues from API business for the quarter grew by 24% at INR344 million as compared to INR278 million same quarter last year.
- Europe revenue was around INR49 crores for Q3 and INR171 crores as of now.
Show source
Aditi Panandikar: So, Europe, for 9 months -- for Q3 Europe has done around INR49 crores.
- Europe revenue was INR167 crores on a YTD basis.
Show source
Aditi Panandikar: INR167 crores we have done on YTD basis.
- Warren Remedies grew by more than 43% this quarter and 38% on a YTD basis, largely due to the success of its brands in the OTC and OTX segments.
Show source
So Warren Remedies have grown by more than 43% this quarter.
- The company had no margin loss from the technology transfer, but had one-time costs associated with it, against product supply over a long period of time, and estimated spending around INR20 crores on an annual basis.
Show source
So, I think we can roughly quantify that on an annual basis we would have spent around INR20 crores?
- Quarterly remediation costs had previously been in the range of INR4.5 crores to INR5 crores and were slightly reduced in the last quarter.
Show source
Now in the last quarter, it is slightly reduced.
- OTC business did INR34 crores this quarter and 94 on a YTD basis.
Show source
INR34 crores this quarter.
Money and capital
- Total debt is around INR900 crores, including INR700 crores in the main business and INR220 crores in WRPL.
Show source
Aditi Panandikar: So our total debt right now sits at around INR900 crores.
- The company had long-term debt of around 590 and a total debt figure of about 920, including short-term debt, and expected long-term debt to be about 550 or 555 at year-end after a scheduled quarter 4 repayment of 28, which it was confident it could fund from cash generation.
Show source
So with that, we'll have at the year-end about close to about 550 or 555, that is the number for long-term.
- The company had scheduled repayments of around 135 to 140 per annum over the next 2 years and was confident it could generate the cash internally, based on growth in various markets and efficiencies reducing overall cost of operation.
Show source
And then next 2 years, we have a significant amount of repayment at around about 135 to 140 per annum.
- The company has been paying back debt as it comes due and feels confident it can continue to do so.
Show source
We have been paying back as and when things get due, and we feel pretty confident to be able to do that.
- The company is undertaking no further capital expenditure and is controlling opex, with work also being done on inventory.
Show source
On one part, we are very careful about no further capital expenditure.
- The company would explore any and every possibility to reduce or lower debt. Replaced by a later filing.
Show source
But yes, of course, we would explore any and every possibility we can to reduce or lower the debt.
What it expects ahead
What management expects
- The company is confident it can keep its consolidated figure at INR150 crores.
Show source
But otherwise, we are confident to keep it at INR150 crores on a consolidated basis.
- The company is confident that its Europe base business will grow at double-digit, and expects Europe revenues to grow at 20% plus over the next few years, with new products offering better market opportunity and margins and being made in optimized plants.
Show source
I'm not just looking at top line growth, but we should look at Europe over the next few years as growing at 20% plus in revenues.
- New introductions are 6% of its top line; management expects double-digit growth but is not confident about 15% growth over a longer horizon.
Show source
Aditi Panandikar: So given that new introductions are 6% of our top line, while the mature products will continue to dominate in the shorter run, soon the new introductions will s tart playing up and making their presence felt.
- OTC business was expected to do INR130 crores during the current financial year.
Show source
Madhav: And I think INR130 crores during the current financial year.
- The company expected its OTC business number to go up by at least 30%, citing energy put into consumer marketing and advertising.
Show source
But safe to say that with the amount of energy we are putting in consumer marketing, in advertising, this number should go up safely by at least 30%.
- The company will be able to sell in the U.S. and Europe and expects further improvement in margin once US FDA or EU qualifies the finished API block at Auric site in Aurangabad.
Show source
As soon as US FDA comes down and qualifies it or EU comes down and qualifies it, we will be able to sell in those markets and then we should see further improvement in margin.
What it is building and selling
Projects and capacity
- The company expected maintenance capex of around 35, 40 max per annum.
Show source
Pramod Ghorpade: Around 35, 40 max per annum would be the maintenance capex required.
Demand and pricing
- Cyclopam grew by 30% at primary last year while prescriptions grew by 16%; this year primary was 15% down, but prescriptions continued to grow.
Show source
Now this year, it is 15% down in primary, but prescriptions continue to grow.
Segments
- About 40% of the API sales Indoco Remedies Limited sells outside is supplied internally to in-house formulations at Indoco.
Show source
In addition to that, about 40% of this -- additional to this is supplied internally to in- house formulations at Indoco.
- Warren Remedies launched 2 new products directly into OTC in Q3, one for its sensitivity basket and the other a superior toothpaste made in-house in R&D for Frank OTC in the general toothpaste market of high-end products.
Show source
And as I mentioned, this quarter, we also Q3 that is we launched 2 new products directly into OTC, one to add further into our sensitivity basket and the other to actually provide a superior toothpaste, which is made in-house in our R&D and which can now feature in Frank OTC in the general toothpaste market of high-end products.
Risks, rules and outside factors
Risks and disputes
- The company has been unable to supply certain products because the site is under remediation, and penalties against orders were confirmed.
Show source
Aditi Panandikar: Because of the site being under remediation, there are certain products we've not been able to supply.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Pratik Kothari: Ma'am first on Europe. So last quarter, we had some issues and there were some approval challenges, which kind of got resolved and you were expecting some growth to come in, but it has actually gone down. So any updates, if any, on Europe specifically?
Answer, aditi panandikar
Aditi Panandikar: Yes. So we had said that there are some approvals coming in. I have to say that between customer and us, there has been some delays. So some of that has got pushed forward by 1 quarter. That's it.
Question
Pratik Kothari: So are they in place now or still some to go?
Answer, aditi panandikar
Aditi Panandikar: Almost. 90% work done. I mean it has not happened in the first month of this quarter but expecting it to turn now. So we should at least get 1, 1.5 months of manufacturing.
Question
Pratik Kothari: Correct. Ma'am second on other expense. Again, our expectation was to kind of curtail it at INR150 crores, INR160 crores at a consol level. We have been -- for last 3, 4 quarters, we have been doing INR170 crores. So anything we can do to control that?
Answer, aditi panandikar
Aditi Panandikar: I think this quarter, we have controlled at a consolidated level Pramod.
Question
Pratik Kothari: Still INR169 crores?
Answer, pramod ghorpade
Pramod Ghorpade: So that includes certain onetime cost, nonrecurring cost which we expect not to repeat. So there are certain remediation costs, which was pending, then there was a cost associated to certain penalties.
Answer, aditi panandikar
Aditi Panandikar: Because of the site being under remediation, there are certain products we've not been able to supply. There are some penalties against orders which was confirmed. So there are many such things. But otherwise, we are confident to keep it at INR150 crores on a consolidated basis.
Question
Pratik Kothari: Can we quantify this nonrecurring onetime for the quarter.
Answer, aditi panandikar
Aditi Panandikar: Around INR8 crores to INR9 crores. Page 4 of 17 Indoco Remedies Limited February 03, 2026 Pratik Kothari: And anything on FDA for our Goa Plant II?
Answer, aditi panandikar
Aditi Panandikar: So as you know, we acquired FPP in June of '23 and we started with a very small portfolio which they had largely involving traded products. Over the last couple of years, we have built the portfolio through our products which we supply through FPP. Of course, the basket has both solid orals as well as sterile. You know we are having certain challenges with sterile products supplied to FPP, but our solids have started doing really very well. So in addition to steriles, which are being supplied from sites that is Plant II, which is not very significant. But I did mention last time we have started sourcing from other sites also. So that is better.
Answer, aditi panandikar
We are also doing much better on the traded business at FPP and the solids that are being supplied to FPP from Indoco has also increased. So net-net, this has -- and we have also got some good orders in the front end. This has helped FPP do much better. And I'm confident going forward, it will do better.
Question
Kenil Mehta: And I would like to know about our new introduction portfolios across our India business. And when should we see our growth going above the market, IPM market… Aditi Panandikar: As you know, we have got a portfolio which is pretty much acute skewed.
Answer, aditi panandikar
And although at a doctor level, we say it is subchronic because we do get support from the mass specialty, we are still not with many of the super specialty doctors. And for the India business at Indoco, our strategy has been very clear to go from acute to subchronic to go from GPs to mass specialty and to move from -- because Indoco is a company which gets more than 60% of its revenues from Tier 3 down -- Tier 2 down. So we are -- we have taken several measures strategically to improve performance in the metros. So as all of these build in, you will see us doing better than the IPM. However, having said that, if you have been studying the IPM carefully, you will see that this year, the acute has been under a lot of stress. And for this quarter, the current quarter, there has been some upside on respiratory. But otherwise, acute has been under a lot of stress.
Answer, aditi panandikar
And what has really grown is cardio and diabeto. So compared to the covered market, we are not lagging too much. In fact, on a MAT basis for December, we are at par or better than our covered market. And it is only when you compare with IPM because then you have to look at the anti-obesity products and all the other things that are going on. But to your question about when can we beat market estimates, like I just told you, for India, our strategies revolve around generation of more prescriptions from the doctors. And here, we are Page 5 of 17 Indoco Remedies Limited February 03, 2026 very confident we are on the right track. So I feel sure that going forward, we will be able to do IPM levels or better.
Question
Kenil Mehta: But the market is growing due to cardiac and diabetics, but we have very less share if you compare, we have seen degrowth over the last 3 years in that segment only. So any particular reason we are not focusing or are we?
Answer, aditi panandikar
Aditi Panandikar: It is a very -- cardio-diabeto is a very tough segment for and already has a lot of competition. At Indoco, we focus more on those therapies, which allow us to have a higher prescriber base than a lot of prescription for a doctor, which is what a super specialty does. However, we are increasingly focused on consulting physicians, increasingly focused on pediatricians, gynecologists. In fact, our gynec prescriptions -- gynec business has grown by almost 15% this year on a Y-o- Y basis. Synergy, which is a division which is having an agenda towards metro centricity and carries one of our big products, Karvol Plus on a Q-o-Q basis also has grown by 26.8%. So these are some healthy signs. About -- we do have some very good products in diabetology, but not the latest molecules.
Answer, aditi panandikar
We have Glychek, Glychek-M, and that is reasonably doing well. But we continue to focus more on the mass specialty.
Question
Kenil Mehta: No, no. Aditi Panandikar: Okay.
Answer, aditi panandikar
So our largest site for APIs is the Patalganga site from where the finished APIs largely come out. We also have a small Kilo manufacturing site where the top line is not very significant. We do manufacture some of our starting material at a very old site, which supports the Patalganga site. In addition to that, the site at Auric, which is under the WRPL, Warren Remedies has also started making KSMs and starting material for our API products, which is then consumed at Patalganga. So this has helped us free more capacity at Patalganga for finished API, and that is what is showing here. Going forward also, we plan to continue to do this. In addition to bringing capacity at Patalganga for finished API, I feel very confident that the finished API block at Auric site in Aurangabad, which is part of the Warren Remedies Group, which is now ready and is taking validation batches of products.
Answer, aditi panandikar
As soon as US FDA comes down and qualifies it or EU comes down and qualifies it, we will be able to sell in those markets and then we should see further improvement in margin. But as such, we manage our API business very well. As you know, the API sales that you see is what we sell Page 6 of 17 Indoco Remedies Limited February 03, 2026 outside. In addition to that, about 40% of this -- additional to this is supplied internally to in- house formulations at Indoco. Kenil Mehta: Understood. So ma'am, going forward, should we expect API business also to touch the INR200 crores run rate yearly?
Answer, aditi panandikar
Aditi Panandikar: Of course. It is at INR200 crores if you consider what is internally transferred.
Question
Kenil Mehta: Okay. Understood. No, I was talking from the outside point of view as we are ramping up from INR25 crores base to INR40 crores-INR45 crores.
Answer, aditi panandikar
Aditi Panandikar: Yes. Next year, I'm very confident. As I told you, this year, the Auric will concentrate more on validation, and we will be restricted to what we can make at Patalganga. But I'm sure that in another 8 to 10 months, we will start getting high revenues from Auric site also and then we can really ramp up our API business.
Question
Kenil Mehta: And ma'am, should we expect some blockbuster drug launch approvals for us as we have got a few in the past and they are near expiring one such as Apixaban where we are first to file along with 2, 3 others?
Answer, aditi panandikar
Aditi Panandikar: There are several coming up for patent expiry or where the date has been sort of where we have settled with innovators and they are all in FPPs portfolio for the next year. So we keep our fingers crossed and stay very positive for these to help us ramp up FPP sales in the next year.
Answer, aditi panandikar
Aditi Panandikar: So, Europe, for 9 months -- for Q3 Europe has done around INR49 crores. And I think INR171 crores we have done as of now.
Answer, aditi panandikar
Aditi Panandikar: INR167 crores we have done on YTD basis.
Show 13 more questions
Question
Ankit Gupta: How much was it last year?
Answer, aditi panandikar
Aditi Panandikar: Equivalent it was. And however, last year, if you remember well, we had major challenges due to the MMP execution because of which the fourth quarter for Europe was extremely poor. This year, in fact, like I mentioned earlier, many of the issues with Phase II of MMP which allowed our -- wherein we have got approval from our customers to now manufacture at the higher batches. And in the new sites are all coming in, we expect the fourth quarter to be much better for Europe. And net-net, I would not like to give you a number at this stage but let us surprise you in a pleasant way. Page 7 of 17 Indoco Remedies Limited February 03, 2026 Ankit Gupta: Sure.
Question
And ma'am, we were also very -- you're also -- like for the coming few years, you are pretty bullish on the European business and expected this to scale to a significant number. So if not for -- the coming quarter, FY '27, if you can let us know how much scale do we expect in the European business?
Answer, aditi panandikar
Aditi Panandikar: So there are -- see, it is -- these are the businesses which are based on generics. And in addition to the base business, which is set to grow at double-digit I'm very confident the new products which will also come in and which have much better market opportunity as well as margins and will be made in the plants, which have been now optimized. I'm not just looking at top line growth, but we should look at Europe over the next few years as growing at 20% plus in revenues. But more importantly, we should be watching the margins to improve on that business.
Question
Ankit Gupta: And on the Warren Remedies, if you can guide us how has been the performance for the quarter and 9 months and next year, how do you see the performance, especially on the profitability in breakeven level?
Answer, aditi panandikar
Aditi Panandikar: Yes. So Warren Remedies have grown by more than 43% this quarter. And I think for YTD basis, it is in 38%. This is largely due to the success we are seeing with our brands in the OTC and OTX segments. If you recall, we had the products like Sensodent-KF, which made a switch from pure Rx to OTX first and then to OTC. Thereafter, we have products like Kidodent which are doing exceedingly well in the OTX segment. And as I mentioned, this quarter, we also Q3 that is we launched 2 new products directly into OTC, one to add further into our sensitivity basket and the other to actually provide a superior toothpaste, which is made in-house in our R&D and which can now feature in Frank OTC in the general toothpaste market of high-end products.
Answer, aditi panandikar
Looking at all this and the new launches that we have planned in the coming months, I feel very confident that the toothpaste business and the Oral Care business in Warren Remedies will go from strength to strength. Coming to the API business, as I mentioned earlier, this year will be a year of -- I think '26-'27 will be a year of consolidation for API, although there will be lot of validation of products at this site, which, of course, it took a formulation team trigger for international audit. Page 8 of 17 Indoco Remedies Limited February 03, 2026 We may not be able to supply to the reg market too much this year. So we are proposing or forecasting a muted top line for API in Warren Remedies, but I feel very confident for the subsidiary to do well overall.
Question
Ankit Gupta: Sure. But should we expect breakeven next year at EBITDA level or given the API performance it will be difficult?
Answer, aditi panandikar
Aditi Panandikar: So there are two challenges to breaking even. One, of course, is the investments in API and the opex and RMPM cost of the validation batches taken for API. But we should not forget that to expect a breakeven on an OTC business in the second year is very tough because we have now really started ramping up our spend on advertising. So which is why when it comes to -- I said when it comes to European business, stay bullish on the margin. I would say when it comes to Warren Remedies, let them breathe and grow sales.
Answer, aditi panandikar
Aditi Panandikar: Yes. So you must have seen that both our subsidiaries have started doing better. These were both fledgling businesses earlier and were giving a drain on the business. So that has improved. In addition to which COGS at even IRL level have improved. This is -- this shows a much better shift in the portfolio, much better shift in the quality of business that we are getting. Growth in prescription, jumping a rank in the prescription audit all indicate that if the demand part of the business is better managed, it's not always about top line.
Answer, aditi panandikar
It's also the quality of business. And I think all of this is resulting in much better control and giving us a much better margin.
Question
Maulik Varia: Okay. Okay. Thank you. And ma'am, you were just mentioning to a participant. So what are we expecting from the FPP portfolio in FY '27? And how many product approvals are we expecting or maybe filing? Some indication or understanding about FPP for FY '27-'28 would be helpful ma'am?
Answer, aditi panandikar
Aditi Panandikar: Okay. '27-'28. So that's a bit far. We have right now visibility for '26-'27, where there is expectation that at least five new products should be launched out of our own portfolio. They will come at various times in the year, so it will be difficult to quantify that. And -- but they are extremely exciting. You must have heard of the lacosamide oral suspension, which got approved recently.
Answer, aditi panandikar
We also have a couple of other products where we have an opportunity to be early and have received the player approval to ship product. That is likely to also help us. But I would be little cautious because the moment I say something to you guys, you expect the next month to do well. But US business is not like this. There is transfer of product first, then there are orders in the market, then you sell them and you know very well what happens in US for the collection. So - - but we are building a very strong business, and I'm very happy to say that. Page 9 of 17 Indoco Remedies Limited February 03, 2026 Maulik Varia: Okay. okay.
Question
And any therapies where you would be able to guide these five new products which you were expecting in FY '27, which therapies are these or any addressable market size for these?
Answer, aditi panandikar
Aditi Panandikar: No, market size, I will not comment. But therapies, I tell you broadly, we have always stuck to two or three therapies for our international markets, especially US. We participate in cardiology, diabetology, and CNS definitely because of Allopurinol which is such a big product in our basket we also look at that therapy and antigout that is. In addition to which, of course, the ophthalmic product basket is great for us. Then in the traded products at FPP, we have got some interesting products even in the Onco segment.
Question
Pratik Kothari: Ma'am on the two lines that we were allowed to restart in Goa for the US sterile, does it contribute anything meaningfully? Or I mean, everything from there comes in after the whole plan gets approved?
Answer, aditi panandikar
Aditi Panandikar: Well, nothing meaningful yet. I'll be very honest. In fact, we have started getting small amounts of sales from sterile, but it's still largely from outsourced, but we have begun.
Question
Pratik Kothari: I'm talking about 7B which is INR2 crores loss on sale and lease back?
Answer, aditi panandikar
So let us see. All these things are different kind of ways of -- we see it when we compare our prescription growth, we get an exact pulse of the secondary demand. I'll just give you an example. Our product Cyclopam last year, which grew by 30% at primary, prescriptions have grown by 16%. Now this year, it is 15% down in primary, but prescriptions continue to grow. Page 11 of 17 Indoco Remedies Limited February 03, 2026 So prescriptions for us are a real indication of the real consumption, and that is not slowing down. Sometimes market sentiment, buying behavior, voice in the field cause these kind of blips in primary push or hold back and that is what results in quarter-to-quarter kind of a change.
Question
Dhwanil Desai: Okay. So again, kind of putting it down more succinc tly, so is it fair or realistic to assume that given whatever portfolio that we have and the seasonality of the nature of the acute business, is it fair that we can grow this business at 15%, let's say, over a longer horizon, maybe 2, 3 years? Is that a fair assumption or is that too much to ask given the maturity of our products?
Answer, aditi panandikar
Aditi Panandikar: So given that new introductions are 6% of our top line, while the mature products will continue to dominate in the shorter run, soon the new introductions will s tart playing up and making their presence felt. So I do feel confident for a double-digit. I'm not so confident about the 15%. But there are -- even when it comes to our legacy products, many of them have -- there is a lot of leverage we can achieve through reach. There are many geographies where we are skewed. So there's a lot to do. It is just not as easy in India to translate, but we are working very hard on it.
Question
Dhwanil Desai: Okay, okay. So I think we used to do that 18% kind of a margin and from whatever that you are seeing qualitatively the US business will have far higher margins and domestic business anyway are good margin businesses, which the growth will come back there. So -- and Europe also you said the margin should improve. So there is a visibility of going back to 18%, 19% kind of a margin, you know, leave aside the timeline. Is that a fair assumption?
Answer, aditi panandikar
Aditi Panandikar: So our total debt right now sits at around INR900 crores. INR700 crores in the main business and INR220 crores in WRPL. We have been paying back as and when things get due, and we feel pretty confident to be able to do that. But yes, of course, we would explore any and every possibility we can to reduce or lower the debt. On one part, we are very careful about no further capital expenditure. We are controlling opex. And I think going forward, therefore, there is a lot of work being done also on the inventory side.
Answer, pramod ghorpade
Pramod Ghorpade: Yes, sure. So this 920-odd number, which includes short-term as well as long-term, while long- term is at the range of 590, and we have another repayment which is scheduled in this quarter 4, which is to the extent of 28, and we are very confident to generate revenue or cash margins to fund the repayment as well as the interest component. So with that, we'll have at the year-end about close to about 550 or 555, that is the number for long-term. And then next 2 years, we have a significant amount of repayment at around about 135 to 140 per annum. And we have worked out forecast estimates, and we are very confident to generate that much cash internally. As madam mentioned, that is purely based on one is about the overall growth in various markets. Second is about the efficiencies, which will bring us another reduction in overall cost of operation.
Answer, pramod ghorpade
Pramod Ghorpade: Around 35, 40 max per annum would be the maintenance capex required. Rohit: Okay.
Question
VP Rajesh: Right. So what was the margin loss because of that? If you can quantify in terms of crores of rupees?
Answer, aditi panandikar
Aditi Panandikar: There is no margin loss, but yes, there are onetime costs associated with technology transfer. But they are against product supply over a long period of time. So, I think we can roughly quantify that on an annual basis we would have spent around INR20 crores?
Question
VP Rajesh: Okay. And do we have a number? What is the total cost of remediation and penalties for the 9 months?
Answer, pramod ghorpade
Pramod Ghorpade: So on a quarterly basis, we used to have remediation in the range of INR4.5 crores to INR5 crores. Now in the last quarter, it is slightly reduced.
Question
VP Rajesh: So, INR20 crores, let's say 4 and 4, 8, and plus this 9, 17 plus 20, roughly about INR35 crores, INR40 crores in this financial year is sort of onetime cost, which would not have been there had you had your US FDA approval. Is that the right...
Answer, aditi panandikar
Aditi Panandikar: I think this quarter, we would have done, I know on YTD basis we have done 94. INR34 crores this quarter. Madhav: So on the OTC business, assuming that the same run rate is going to be continued. So I think what will be next year assumption for the OTC business madam?
Answer, aditi panandikar
Aditi Panandikar: Yes. Madhav: And I think INR130 crores during the current financial year. And for the next financial year, what is the expectation for the next financial year for the OTC business?
Answer, aditi panandikar
Aditi Panandikar: You know, people in our brotherhood would have told me I should not be giving forward- looking projections. But safe to say that with the amount of energy we are putting in consumer marketing, in advertising, this number should go up safely by at least 30%. Madhav: Yes, because we are good to see that you are giving some brand extensions also. So I think the business should go better in the next year as well.
Questions about this call
- When was the Indoco Remedies Q3 FY26 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 9 Feb 2026. This page is built from that transcript.
- What does this page list?
- 36 statements from the transcript across 7 topics, 24 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 23 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.